Eli Lilly Shares Plummet on Disappointing Obesity Pill Data Despite Q2 Earnings Beat

Obesity Pill Trial Results

• 📉 Eli Lilly shares experienced a significant drop of over 14%, driven by disappointing data from its upcoming obesity treatment pill.
• 🎯 The trial showed participants lost about 12% of their body weight at the highest dose after a year, falling short of the 15% benchmark set by WGOI.
• ⚠️ Approximately 10% of patients on the highest dose discontinued the pill due to adverse events, primarily GI issues, which is slightly higher than other GLP1s.
• ❓ A surprising 25% of patients at the highest dose stopped taking the drug for any reason, with the exact causes yet to be fully explained.

Company and Investor Perspectives

• 🗣️ Eli Lilly CEO Dave Ricks stated the company is happy with the results, aiming for a convenient, scalable oral pill with competitive weight loss.
• 📈 The company also reported better-than-expected second quarter results, raising its full-year sales and profit forecast, largely due to sales of Mjaro and Zepbound.
• 📌 However, this positive financial news was overshadowed by the concerning data from the obesity pill trial.

Market Reaction and Concerns

• 💸 Investors and analysts are weighing the impact of the disappointing weight loss percentage and the high dropout rate.
• 💬 The uncertainty surrounding the reasons for patient dropouts is a major concern, as sustained use is critical for sales estimates.
• 📉 The market reaction suggests that the few percentage points difference in weight loss and patient retention are significant for investors.
• ⏳ The full results are expected to be presented next month, which may provide more clarity on the trial outcomes.